| Tbio | E3 ubiquitin-protein ligase MYLIP |
E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR.
The ERM protein family members ezrin, radixin, and moesin are cytoskeletal effector proteins linking actin to membrane-bound proteins at the cell surface. Myosin regulatory light chain interacting protein (MYLIP) is a novel ERM-like protein that interacts with myosin regulatory light chain and inhibits neurite outgrowth. [provided by RefSeq, Jul 2008]
The ERM protein family members ezrin, radixin, and moesin are cytoskeletal effector proteins linking actin to membrane-bound proteins at the cell surface. Myosin regulatory light chain interacting protein (MYLIP) is a novel ERM-like protein that interacts with myosin regulatory light chain and inhibits neurite outgrowth. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Endometriosis | 540 | 0.0 | 0.0 |
| Disease | Target Count | P-value |
|---|---|---|
| lung adenocarcinoma | 2716 | 2.7e-06 |
| atypical teratoid / rhabdoid tumor | 5112 | 3.6e-06 |
| group 4 medulloblastoma | 1855 | 4.5e-06 |
| malignant mesothelioma | 3232 | 7.9e-06 |
| tuberculosis and treatment for 6 months | 409 | 1.6e-04 |
| ulcerative colitis | 1819 | 1.7e-04 |
| osteosarcoma | 7950 | 2.1e-04 |
| adult high grade glioma | 3801 | 3.1e-03 |
| acute myeloid leukemia | 783 | 5.4e-03 |
| adrenocortical carcinoma | 1428 | 5.9e-03 |
| ovarian cancer | 8520 | 9.4e-03 |
| pancreatic carcinoma | 562 | 1.0e-02 |
| pancreatic cancer | 2398 | 1.0e-02 |
| medulloblastoma, large-cell | 6241 | 2.6e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Autosomal dominant nonsyndromic deafness 31 | 3 | 4.848 | 2.4 |
| Autosomal dominant nonsyndromic deafness 21 | 3 | 4.612 | 2.3 |
| Autosomal dominant nonsyndromic deafness 13 | 2 | 3.677 | 1.8 |
| Charcot-Marie-Tooth disease type 4D | 1 | 3.279 | 1.6 |
| Disease | log2 FC | p |
|---|---|---|
| acute myeloid leukemia | 1.200 | 5.4e-03 |
| adrenocortical carcinoma | -1.089 | 5.9e-03 |
| adult high grade glioma | -1.100 | 3.1e-03 |
| atypical teratoid / rhabdoid tumor | -1.200 | 3.6e-06 |
| group 4 medulloblastoma | -1.300 | 4.5e-06 |
| lung adenocarcinoma | -1.200 | 2.7e-06 |
| malignant mesothelioma | 1.500 | 7.9e-06 |
| medulloblastoma, large-cell | -1.300 | 2.6e-02 |
| osteosarcoma | 1.724 | 2.1e-04 |
| ovarian cancer | 1.200 | 9.4e-03 |
| pancreatic cancer | -1.200 | 1.0e-02 |
| pancreatic carcinoma | -1.200 | 1.0e-02 |
| tuberculosis and treatment for 6 months | 1.100 | 1.6e-04 |
| ulcerative colitis | -1.100 | 1.7e-04 |
MLCYVTRPDAVLMEVEVEAKANGEDCLNQVCRRLGIIEVDYFGLQFTGSKGESLWLNLRNRISQQMDGLA 1 - 70 PYRLKLRVKFFVEPHLILQEQTRHIFFLHIKEALLAGHLLCSPEQAVELSALLAQTKFGDYNQNTAKYNY 71 - 140 EELCAKELSSATLNSIVAKHKELEGTSQASAEYQVLQIVSAMENYGIEWHSVRDSEGQKLLIGVGPEGIS 141 - 210 ICKDDFSPINRIAYPVVQMATQSGKNVYLTVTKESGNSIVLLFKMISTRAASGLYRAITETHAFYRCDTV 211 - 280 TSAVMMQYSRDLKGHLASLFLNENINLGKKYVFDIKRTSKEVYDHARRALYNAGVVDLVSRNNQSPSHSP 281 - 350 LKSSESSMNCSSCEGLSCQQTRVLQEKLRKLKEAMLCMVCCEEEINSTFCPCGHTVCCESCAAQLQSCPV 351 - 420 CRSRVEHVQHVYLPTHTSLLNLTVI 421 - 445 //
